Eiger Biopharmaceuticals (EIGR) vs. Iovance Biotherapeutics (IOVA) Critical Contrast

Share on StockTwits

Eiger Biopharmaceuticals (NASDAQ:EIGR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Eiger Biopharmaceuticals and Iovance Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger Biopharmaceuticals N/A -156.68% -83.59%
Iovance Biotherapeutics N/A -48.14% -45.66%

Valuation and Earnings

This table compares Eiger Biopharmaceuticals and Iovance Biotherapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eiger Biopharmaceuticals N/A N/A -$42.44 million ($4.86) -2.09
Iovance Biotherapeutics N/A N/A -$92.06 million ($1.41) -8.46

Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Eiger Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Eiger Biopharmaceuticals has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500.

Institutional and Insider Ownership

69.3% of Eiger Biopharmaceuticals shares are held by institutional investors. Comparatively, 87.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.9% of Eiger Biopharmaceuticals shares are held by company insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Eiger Biopharmaceuticals and Iovance Biotherapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger Biopharmaceuticals 0 0 7 0 3.00
Iovance Biotherapeutics 0 0 8 0 3.00

Eiger Biopharmaceuticals currently has a consensus price target of $33.29, indicating a potential upside of 227.29%. Iovance Biotherapeutics has a consensus price target of $24.44, indicating a potential upside of 104.84%. Given Eiger Biopharmaceuticals’ higher probable upside, research analysts clearly believe Eiger Biopharmaceuticals is more favorable than Iovance Biotherapeutics.

Summary

Iovance Biotherapeutics beats Eiger Biopharmaceuticals on 7 of the 10 factors compared between the two stocks.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply